Videos

An expert on chronic lymphocytic leukemia discusses adverse effects encountered by patients who are receiving BTK inhibitors or venetoclax-based regimens.

Josie Montegaard, MSN, AGPCNP-BC, provides clinical insights on her approach to counseling patients who are receiving treatment for chronic lymphocytic leukemia.

After a cancer diagnosis, toxic positivity can be unhelpful, though forced joy may bring light to a difficult situation, a survivor and advocate said.

SurVaxM, which is being studied in gliobastoma, targets a certain protein that is found on the brain cancer cells.

Presurgical paclitaxel, Herceptin and Perjeta showed “incredible efficacy” in treatment of HER2-positive breast cancer.

Rybrevant plus Leclaza had promising response and progression-free survival rates in patients with EGFR-mutant non-small cell lung cancer.

Dr Linhares discusses newer combination therapies for the treatment of patients with chronic lymphocytic leukemia, highlighting ibrutinib and venetoclax, which is being studied in the CAPTIVATE trial.

Turning the focus to ibrutinib-based therapy, Yuliya Linhares, MD, gives an overview of the RESONATE study.

Expert perspectives on the SEQUOIA study, which is investigating zanubrutinib in patients with chronic lymphocytic leukemia.

Yuliya Linhares, MD, discusses the CLL14 study, which is looking at venetoclax plus obinutuzumab in patients with previously untreated chronic lymphocytic leukemia.

Focusing on acalabrutinib-based treatment, Yuliya Linhares, MD, discusses results from the ELEVATE TN clinical trial.

A general overview of efficacy and safety data for current treatment options for patients with chronic lymphocytic leukemia.

“I think there is a very near future where we have available breast cancer vaccines for all of us, our children and for everybody,” said Kristen Dahlgren.

An oncology nurse discusses what patients should know before BiTE therapy, and what they can do if they do not have a social support system.

Josie Montegaard, MSN, AGPCNP-BC, offers expert perspectives on treatment considerations in CLL, focusing on BTK inhibitors and venetoclax-based therapy.

Dr Linhares provides clinical insights on factors that guide treatment decisions for patients with chronic lymphocytic leukemia, such as comorbidities and disease biology.

Jessica McDade, B.S.N., RN, OCN, explains how she helps make her patients’ experience “a little less daunting” during their hospital stay.

For patients with blood cancers, CAR-T cell therapy has been a “mind-blowing” advancement for treatment in the cancer space.

An oncology nurse explained the impacts that organizations like Wonders & Worries can make on children of patients with cancer.

Focusing on the first-line setting, Yuliya Linhares, MD, gives an overview of first-line treatment options for patients with chronic lymphocytic leukemia.

Josie Montegaard, MSN, AGPCNP-BC, discusses the goals of treatment for patients with chronic lymphocytic leukemia and how they may vary depending on factors such as age, risk level, and symptoms.

Leaning on a community of oncology nurses, other patients and survivors can help ease the burden of receiving a cancer diagnosis, said Kristen Dahlgren.

Before patients receive Enhertu for HER2-positive solid tumors, it’s important to know about the potential side effects.

For patients with lymphoma or multiple myeloma, speaking up about symptoms of cytokine release syndrome can be lifesaving.

During chemo shortages, nurses have helped many patients receive enough treatment, measuring them down to the “minutiae of the milligrams.”

Dr Linhares gives a comprehensive overview of tests a patient might expect to undergo at the time of diagnosis and why they are important.

Yuliya P.L Linhares, MD, and Josie Montegaard, MSN, AGPCNP-BC, introduce themselves and give an overview of chronic lymphocytic leukemia (CLL), highlighting symptoms and patient presentation.

With Carvykti now approved for pretreated myeloma, there are conversations that patients should have with their providers before treatment, a nurse said.

Treatment for HER2-positive breast cancer depends on staging and can be intensified or de-escalated depending on disease characteristics, explained Dr. Debu Tripathy.

Comprehensive biomarker testing and “timely” testing is “important” for patients with a specific lung cancer subset, an expert said.